Medical imaging has become an essential component of modern clinical trials, supporting efficacy assessments, safety evaluations, and regulatory decision-making across therapeutic areas such as oncology, ophthalmology, Gastroenterology and musculoskeletal disorders. As imaging endpoints play a greater role in demonstrating treatment outcomes, ensuring consistency across multiple investigative sites has become one of the most significant operational challenges in clinical research.

Centralized imaging review addresses this challenge by bringing consistency to image acquisition, review, and quality oversight across all participating sites. It helps sponsors generate reliable imaging data while supporting robust endpoint evaluation and regulatory expectations.

At Lambda Therapeutic Research, centralized imaging review is integrated into late-phase clinical development through experienced imaging specialists, standardized workflows, digital imaging technologies, and close collaboration with investigative sites. This integrated approach helps sponsors generate reliable imaging data while maintaining consistency from image acquisition through endpoint evaluation.

The challenge of imaging consistency

Unlike laboratory data, medical images are highly dependent on  how they are acquired, transferred, and reviewed. variations in imaging equipment, acquisition protocols, technician expertise, and site practices can all affect image quality and ultimately influence endpoint evaluation. Common challenges in multicenter imaging studies include:

• Poor image quality due to incorrect acquisition techniques
• Missing or incomplete imaging anatomy  
• Delayed image uploads
• Imaging visits performed outside protocol-defined windows
• Variability in image interpretation across sites

Even seemingly minor inconsistencies can increase image rejection rates, generate additional queries, delay endpoint assessments, and create unnecessary operational burden for sponsors and investigative sites alike.

Achieving reliable imaging endpoints requires more than experienced image reviewers. It depends on standardized processes, proactive communication, and continuous operational oversight throughout the study.

Why centralized imaging review makes a difference

Centralized imaging review establishes a uniform process for image evaluation across every participating site. Rather than relying on individual site assessments, images are reviewed using predefined criteria and standardized workflows, helping reduce variability throughout the study.

For sponsors conducting multicenter clinical trials, this provides several advantages:

• Standardized image review and reporting
• Improved quality control throughout the imaging workflow
• Centralized query management
• Better documentation and audit readiness
• Greater confidence in imaging endpoints across all participating sites

By applying the same quality standards throughout the study, sponsors can generate more consistent imaging data while minimizing operational variability.

Building quality at the site level

High-quality imaging starts before the first participant is enrolled. Successful imaging programs rely on well-prepared investigative sites that understand protocol requirements and imaging procedures from the outset. Site qualification, protocol-specific imaging manuals, investigator meetings, and structured training all contribute to improving image quality before patient enrollment begins.

During study execution, continuous communication remains equally important. Prompt query resolution, proactive follow-ups, and regular engagement with sites help address operational issues before they affect endpoint evaluation or study timelines.

This structured approach has helped Lambda minimize common site-level challenges such as poor image quality, delayed uploads, missing images, and inconsistent implementation of imaging protocols across multicenter studies.

Technology supports netter Imaging Workflows

Modern imaging studies generate thousands of images across multiple countries and investigative sites. Efficient management of this data requires technology designed specifically for clinical trial workflows.

Lambda supports centralized imaging review through MI-LP, its customized web-based imaging platform that enables secure image upload, centralized analysis, query management, and image storage. The platform supports 21 CFR Part 11 compliant electronic workflows while providing investigators and sponsors with efficient and transparent imaging management.

Digital platforms improve efficiency, but consistent imaging outcomes still depend on experienced reviewers, well-trained sites, and proactive operational support throughout the study.

Experience across multiple therapeutic areas

Imaging requirements vary considerably across therapeutic areas, requiring both imaging expertise and operational experience to ensure consistent endpoint evaluation. Lambda has supported oncology, ophthalmology, gastroenterology and musculoskeletal clinical trials using imaging modalities including MRI, CT, PET, DXA, Optical Coherence Tomography (OCT), Fluorescein Angiography (FA), and Color Fundus Photography (CFP). This experience includes studies involving:

Oncology	Breast cancer, lung cancer, prostate cancer, and lymphoma
Ophthalmology	Diabetic retinopathy, wet and dry age-related macular degeneration (AMD), retinal vein occlusion, and ocular safety assessments
Gastroenterology	Ulcerative Colitis
Musculoskeletal	Osteoporosis and bone safety evaluations

Working across these diverse indications has enabled Lambda to establish standardized imaging processes while adapting to the unique endpoint requirements of each clinical program.

This experience enables Lambda to identify and address imaging challenges early, reducing operational variability while supporting consistent endpoint evaluation throughout the study.

Operational experience that supports reliable endpoints

Centralized imaging review requires coordination between radiologists, clinical operations teams, project managers, and investigative sites throughout the study lifecycle. Lambda’s centralized imaging capabilities include:

• A panel of qualified radiologists
• Centralized image reading and reporting
• Standardized imaging workflows
• Site training and investigator support
• Query management and quality oversight
• Digital imaging solutions designed for clinical trials

Lambda has supported imaging studies involving 350+ investigative sites globally, with more than 10,000 medical images reviewed across oncology, ophthalmology, and musculoskeletal clinical trials. The team’s experience includes support for 17 oncology studies, 4 global ophthalmology studies, 1 Gastroenterology study and 2 global musculoskeletal studies, with imaging operations conducted under inspections by DCGI, US FDA, and EMA.

Beyond image review, Lambda works closely with investigators throughout study execution to address operational challenges through training, proactive communication, centralized quality oversight, and structured query management. These efforts help reduce image rejection rates, improve protocol adherence, and support consistent endpoint evaluation across multicenter clinical trials.

Reliable endpoints begin with consistent imaging

As imaging endpoints become increasingly important in clinical development, sponsors need more than imaging technology. They need a partner with the operational experience to deliver consistent image quality, standardized review processes, and reliable endpoint evaluation across every investigative site.

These activities demonstrate the strength of our quality systems and our readiness to support sponsors during regulatory inspections and client audits.

Ready to strengthen your imaging strategy?

Whether you’re planning an oncology, ophthalmology, musculoskeletal, or other imaging-intensive clinical trial, connect with our experts to discuss your medical imaging requirements.